Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Milestones :: Perspectives :: Research


Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment


Russia: Sputnik V – “the first registered COVID-19 vaccine”
Press Releases
RDIF and UNICEF sign Sputnik V vaccine supply agreement
Moscow, May 27, 2021 – Human Vaccine LLC, a wholly owned subsidiary of the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the signing of an agreement for the supply of 220 million doses of two-dose Sputnik V Russian COVID-19 vaccine with the United Nations International Children’s Emergency Fund (UNICEF). This amount is sufficient to vaccinate 110 million people.
The supply agreement with UNICEF for Sputnik V vaccine will broaden access to help meet vaccine demand around the world. Procurement and delivery of the vaccine by UNICEF is subject to the vaccine receiving WHO Emergency Use Listing. The decision is expected soon on the Sputnik V application for WHO Emergency Use Listing that was submitted in October 2020.
Concurrently, RDIF will be holding a separate discussion with Gavi, the Vaccine Alliance to see the Sputnik V vaccine considered for inclusion in the COVAX Facility’s Portfolio of COVID-19 vaccines…
[See UNICEF announcement just below]

A study in Argentina confirms Sputnik V highly-effective against Manaus variant of coronavirus
Press release, 24.05.2021

RDIF and Panacea Biotec launch the production of Sputnik V in India
Press release, 24.05.2021
…The first batch produced at Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control. Full-scale production of the vaccine is due to start this summer. Company’s facilities comply with GMP standards and are prequalified by WHO.
Sputnik V was registered in India under the emergency use authorization procedure on April 12, 2021 and vaccination against coronavirus with the Russian vaccine started on May 14. As announced in April, RDIF and Panacea have agreed to produce 100 million doses per year of Sputnik V…



UNICEF signs supply agreement for Sputnik V COVID-19 vaccine
News note 27 May 2021
NEW YORK/COPENHAGEN, 27 May 2021 –  UNICEF and Human Vaccine (Limited Liability Company), a wholly-owned subsidiary of the Russian Direct Investment Fund (RDIF), today announced a long-term agreement (LTA) for the supply of the Sputnik V COVID-19 vaccine. This is the fourth long-term supply agreement UNICEF has signed with a COVID-19 vaccine manufacturer. So far this year, UNICEF has signed such agreements with the Serum Institute of India, Pfizer and AstraZeneca.
Procurement by UNICEF under this agreement is conditional on the product achieving an Emergency Use Listing from WHO, to confirm the quality, safety and efficacy of the vaccine.
In addition, an Advance Purchase Agreement (APA) with Gavi, the Vaccine Alliance, will also be needed for procurement to begin on behalf of the COVAX Facility. Should the COVAX Facility decide to enter into an advance purchase agreement for the supply of the Sputnik V vaccine, UNICEF will be ready to deliver as soon as regulatory milestones have been met. At this point, UNICEF through this LTA, stands ready to access up to 220 million doses of the vaccine available for supply in 2021, to meet country demand.  The Sputnik V vaccine consists of two different components of the vaccine to be administered 21 days apart. An exact delivery schedule will be determined in collaboration with the manufacturer…